Literature DB >> 11179833

Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.

K Miyajima1, S Tamiya, Y Oda, T Adachi, T Konomoto, H Toyoshiba, K Masuda, M Tsuneyoshi.   

Abstract

To investigate the etiology of leiomyosarcoma, we examined abnormalities of p53 and its regulation in 13 cases of leiomyosarcoma using fresh tumor specimens. We estimated p53 and MDM2 mRNA level and MDM2 gene amplification using a real-time semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) based on the TaqMan fluorescence method. We also used immunohistochemistry (IHC) for p53 and MDM2 protein overexpression, polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) and direct sequencing to detect p53 mutation. Eight of the 13 cases (62%) showed an overexpression of p53 protein on IHC and eight of 13 cases (62%) had p53 gene point mutations. Five of the 13 cases (38%) showed positive staining for MDM2 protein and only one case (7.7%) demonstrated MDM2 gene amplification. The relative p53 mRNA level of the tumors compared with normal tissue ranged from 1.14 to 12.19 arbitrary units (AU), and the MDM2 mRNA level ranged from 1.06 to 17.17 AU. The mRNA level in the p53-positive cases was higher than in the negative cases (positive: 7.70 AU on average; negative: 3.38 AU on average; P=0.0344). However, there was no significant correlation between the MDM2 mRNA level and other factors, such as p53 IHC, p53 mutation status, p53 mRNA level and MDM2 IHC. Our results indicate that p53 abnormalities are major events and that an increasing level of p53 mRNA is associated with an overexpression of p53 protein in leiomyosarcoma and they may play an important role in the tumorigenesis in this tumor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179833     DOI: 10.1016/s0304-3835(00)00607-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.

Authors:  P Alhopuro; S K Ylisaukko-Oja; W J Koskinen; P Bono; J Arola; H J Järvinen; J-P Mecklin; T Atula; R Kontio; A A Mäkitie; S Suominen; I Leivo; P Vahteristo; L-M Aaltonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

Review 2.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

3.  The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.

Authors:  Hang Li; Qian Liu; Zhen Wang; Runping Fang; Yu Shen; Xiaoli Cai; Yuen Gao; Yinghui Li; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

4.  The E-cadherin repressor slug and progression of human extrahepatic hilar cholangiocarcinoma.

Authors:  Ke-jun Zhang; Dong-sheng Wang; Shao-yan Zhang; Xue-long Jiao; Chun-wei Li; Xin-sheng Wang; Qin-chao Yu; Hai-ning Cui
Journal:  J Exp Clin Cancer Res       Date:  2010-07-01

5.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09

6.  Clinical efficacy of vorinostat in a patient with leiomyosarcoma.

Authors:  Jin Lee; Colin McGuire
Journal:  Clin Med Insights Oncol       Date:  2012-02-01

7.  Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.

Authors:  Takuma Hayashi; Yuto Shimamura; Taro Saegusa; Akiko Horiuchi; Yukihiro Kobayashi; Nobuyoshi Hiraoka; Yae Kanai; Hiroyuki Aburatani; Kenji Sano; Ikuo Konishi
Journal:  Gene Regul Syst Bio       Date:  2008-07-22

8.  p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.

Authors:  M Dimitriadi; G Poulogiannis; L Liu; L M Bäcklund; D M Pearson; K Ichimura; V P Collins
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.